BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-19 out of 19 found
  Current Search:  famvir: 19     

HTML
100%
Novartis Finds Defense in Alcon
When Bernstein Research upgraded Novartis NVS to outperform in May, the firm dubbed the stock one of the three best-positioned drugmakers to withstand future patent expirations.

Novartis' plan to acquire a majority stake in fellow Swiss...

TheStreet.com:  Jul 8 2008 10:37PM
Matching: famvir
Find similar documents
HTML
100%
Novartis Finds Defense in Alcon
When Bernstein Research upgraded Novartis NVS to outperform in May, the firm dubbed the stock one of the three best-positioned drugmakers to withstand future patent expirations.

Novartis' plan to acquire a majority stake in fellow Swiss...

TheStreet.com:  Jul 8 2008 8:43PM
Matching: famvir
Find similar documents
HTML
100%
Novartis Finds Defense in Alcon
When Bernstein Research upgraded Novartis NVS The wave of patent expiry, pricing pressures as well as higher regulatory hurdles in the U.S.

have already begun to plague Big Pharma companies.

Refocusing and restructuring initiatives have...

TheStreet.com:  Jul 8 2008 8:19PM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on FORTE Trial
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

(NASDAQ: TEVA - News) today announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as...

Yahoo! Canada:  Jul 7 2008 6:26AM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on FORTE Trial
Author : TEVA-PHARMACEUTICAL Category : Press Release News Alerts by Email click here ) News | Home JERUSALEM - (Business Wire) Teva Pharmaceutical Industries Ltd.

(NASDAQ: TEVA) today announced top-line results from a Phase III study...

Earthtimes.org:  Jul 7 2008 6:23AM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on FORTE Trial
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

(NASDAQ: TEVA - News) today announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability of glatiramer acetate (GA) 40mg as...

Business Wire via Yahoo!:  Jul 7 2008 6:17AM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on Generic Seroquel Liti
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

(Nasdaq: TEVA) announced today that the U.S.

District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug...

Citybizlist:  Jul 3 2008 8:22PM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on Generic Seroquel(R) Litigation
JERUSALEM - (Business Wire) Teva Pharmaceutical Industries Ltd.

(Nasdaq: TEVA) announced today that the U.S.

District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug...

Earthtimes.org:  Jul 1 2008 8:46PM
Matching: famvir
Find similar documents
HTML
100%
Teva Provides Update on Generic Seroquel(R) Litigation
JERUSALEM -- (Business Wire) Teva Pharmaceutical Industries Ltd.

(Nasdaq: TEVA) announced today that the U.S.

District Court for the District of New Jersey has issued a decision in its litigation over the Company's Abbreviated New Drug...

Stockwatch:  Jul 1 2008 8:29PM
Matching: famvir
Find similar documents
HTML
100%
Teva Receives First U.S. Approval for Generic Risperdal(R) Tablets; Commences Commercial Launch
JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

(NASDAQ:TEVA - News) announced today that the U.S.

Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA)...

Yahoo! Canada:  Jun 30 2008 7:50PM
Matching: famvir
Find similar documents
HTML
100%
Teva Receives First U.S. Approval for Generic Risperdal(R) Tablets; Commences Commercial Launch
JERUSALEM, Israel -- (Business Wire) Teva Pharmaceutical Industries Ltd.

(NASDAQ:TEVA) announced today that the U.S.

Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to...

Stockwatch:  Jun 30 2008 7:38PM
Matching: famvir
Find similar documents
HTML
100%
Teva Receives First U.S. Approval for Generic Risperdal(R) Tablets; Commences Commercial Launch
Author : TEVA-PHARMACEUTICAL Category : Press Release News Alerts by Email click here ) News | Home JERUSALEM, Israel - (Business Wire) Teva Pharmaceutical Industries Ltd.

(NASDAQ:TEVA) announced today that the U.S.

Food and Drug...

Earthtimes.org:  Jun 30 2008 7:36PM
Matching: famvir
Find similar documents
HTML
100%
Teva Receives First U.S. Approval for Generic Risperdal(R) Tablets; Commences Commercial Launch
JERUSALEM, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd.

(NASDAQ:TEVA - News) announced today that the U.S.

Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA)...

Business Wire via Yahoo!:  Jun 30 2008 7:33PM
Matching: famvir
Find similar documents
HTML
100%
Teva Announces Tentative Approval of Generic Diovan(R) Tablets
JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd.

(Nasdaq: TEVA ) announced today that the U.S.

Food and Drug Administration has granted tentative approval for the Companys Abbreviated New Drug Application (ANDA) to market...

Healthcare Sales & Marketing Network:  Jun 13 2008 3:00AM
Matching: famvir
Find similar documents
HTML
100%
Management of Herpes Simplex Infections Reviewed
Describe the epidemiology of herpes simplex virus infections.

Identify recommend medication regimens for the acute and suppressive treatment of herpes simplex virus infections.

Authors and Disclosures Laurie Barclay, MD Disclosure:...

Medscape:  Jun 11 2008 10:13PM
Matching: famvir
Find similar documents
HTML
100%
Teva Announces Launch Of Generic Wellbutrin XL(R) Tablets, 150 Mg
(NASDAQ: TEVA) announced that it has begun commercially shipping Bupropion Hydrochloride Extended-Release Tablets, 150 mg, the generic version of Biovail Corporation's antidepressant Wellbutrin XL Tablets, pursuant to its March 2007...
Medical News Today:  Jun 2 2008 3:30PM
Matching: famvir
Find similar documents
HTML
100%
Teva Announces Launch of Generic Wellbutrin XL(R) Tablets, 150 mg
JERUSALEM, Israel--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd.

(NASDAQ: TEVA ) announced today that it has begun commercially shipping Bupropion Hydrochloride Extended-Release Tablets, 150 mg, the generic version of Biovail...

Healthcare Sales & Marketing Network:  May 30 2008 7:59PM
Matching: famvir
Find similar documents
HTML
100%
Teva Announces Launch of Generic Wellbutrin XL(R) Tablets, 150 mg
Teva Pharmaceutical Industries Ltd.

(NASDAQ: TEVA) announced today that it has begun commercially shipping Bupropion Hydrochloride Extended-Release Tablets, 150 mg, the generic version of Biovail Corporations antidepressant Wellbutrin XL...

Genetic Engineering News:  May 30 2008 3:53PM
Matching: famvir
Find similar documents
HTML
100%
Novartis Q1 earnings beat forecasts, confirms outlook UPDATE
(Updating with details on outlook, EBIT, segment performance, restructuring, Alcon) ZURICH (Thomson Financial) - Novartis AG.

said first quarter net profit from continuing operations rose to $2.308 billion from $2.092 billion in the same...

Sharewatch:  Apr 21 2008 5:23AM
Matching: famvir
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.